Alexander Hardy, Genentech CEO (via LinkedIn)
June 20, 2023 02:15 PM EDT
People
Law

Q&A with Genen­tech CEO Alexan­der Hardy on Medicare's drug price ne­go­ti­a­tions

Zachary Brennan

Senior Editor

Be­fore and af­ter it was ac­quired by Roche, Genen­tech has made a name for it­self with bi­o­log­ics — the large mol­e­cules that Con­gress re­cent­ly af­ford­ed 13 …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

A service from the Financial Times